A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies

NCT05836896 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

16

Enrollment

OTHER

Sponsor class

Conditions

Neoplasms
Relapsed Diffuse Large B-cell Lymphoma (DLBCL)
Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Multiple Myeloma, Refractory
Multiple Myeloma in Relapse

Interventions

GENETIC: MDC-CAR-BCMA001 (BCMA directed CAR T-cells)

Sponsor

Technische Universität Dresden

Collaborators

[object Object]